HomeCompareEFRMF vs MRK

EFRMF vs MRK: Dividend Comparison 2026

EFRMF yields 6451.61% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFRMF wins by $746046519283998.88M in total portfolio value
10 years
EFRMF
EFRMF
● Live price
6451.61%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$746046519283998.88M
Annual income
$723,972,000,481,503,000,000.00
Full EFRMF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EFRMF vs MRK

📍 EFRMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFRMFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFRMF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFRMF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFRMF
Annual income on $10K today (after 15% tax)
$548,387.10/yr
After 10yr DRIP, annual income (after tax)
$615,376,200,409,277,500,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, EFRMF beats the other by $615,376,200,409,277,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFRMF + MRK for your $10,000?

EFRMF: 50%MRK: 50%
100% MRK50/50100% EFRMF
Portfolio after 10yr
$373023259641999.44M
Annual income
$361,986,000,240,751,500,000.00/yr
Blended yield
97.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EFRMF
No analyst data
Altman Z
-10.4
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFRMF buys
0
MRK buys
0
No recent congressional trades found for EFRMF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFRMFMRK
Forward yield6451.61%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$746046519283998.88M$56.8K
Annual income after 10y$723,972,000,481,503,000,000.00$9,798.13
Total dividends collected$744564070034128.50M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EFRMF vs MRK ($10,000, DRIP)

YearEFRMF PortfolioEFRMF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$655,861$645,161.29$11,206$366.19+$644.7KEFRMF
2$40,247,222$39,545,450.12$12,650$502.35+$40.23MEFRMF
3$2,311,031,117$2,267,966,589.88$14,407$694.19+$2311.02MEFRMF
4$124,181,822,284$121,709,018,988.28$16,585$967.82+$124181.81MEFRMF
5$6,244,985,365,552$6,112,110,815,708.32$19,342$1,363.89+$6244985.35MEFRMF
6$293,945,892,838,957$287,263,758,497,816.90$22,913$1,947.19+$293945892.82MEFRMF
7$12,951,203,390,243,552$12,636,681,284,905,868.00$27,662$2,823.89+$12951203390.22MEFRMF
8$534,203,501,715,883,900$520,345,714,088,323,260.00$34,159$4,173.35+$534203501715.85MEFRMF
9$20,630,391,404,201,763,000$20,058,793,657,365,766,000.00$43,337$6,308.80+$20630391404201.72MEFRMF
10$746,046,519,283,998,900,000$723,972,000,481,503,000,000.00$56,776$9,798.13+$746046519283998.88MEFRMF

EFRMF vs MRK: Complete Analysis 2026

EFRMFStock

East Africa Metals Inc., a mineral exploration company, focuses on the identification, acquisition, exploration, development, and sale of base and precious mineral resource properties in the Federal Democratic Republic of Ethiopia and the United Republic of Tanzania. The company primarily explores for gold, copper, silver, and zinc deposits. Its principal assets and interests include a 70% interest in the Harvest property, as well as 100% interest in the Adyabo project that comprises two exploration licenses covering 195 square kilometers situated in the Arabian Nubian Shield in northern Ethiopia; and an interest in the Handeni property comprising two mining licenses covering 9.9 square kilometers, and contiguous mineral tenures totaling approximately 83.5 square kilometers located in northeastern Tanzania. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Full EFRMF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EFRMF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFRMF vs SCHDEFRMF vs JEPIEFRMF vs OEFRMF vs KOEFRMF vs MAINEFRMF vs JNJEFRMF vs ABBVEFRMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.